Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [ 3H]2-furoyl-LIGRL-NH 2, to human PAR2

Toru Kanke, Hiroyuki Ishiwata, Mototsugu Kabeya, Masako Saka, Takeshi Doi, Yukio Hattori, Atsufumi Kawabata, Robin Plevin

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


To determine the binding characteristics of a highly potent agonist for protease-activated receptor-2 (PAR2), 2-furoyl-Leu-Ile-Gly-Arg-Leu-amide (2-furoyl-LIGRL-NH 2), whole-cell binding assays were performed utilising a radioactive ligand, [ 3H]2-furoyl-LIGRL-NH 2. Specific binding of [ 3H]2-furoyl-LIGRL-NH 2 was observed in NCTC2544 cells, dependent upon PAR2 expression, and competitively displaced by the addition of unlabeled PAR2 agonists. Scatchard analysis of specific saturation binding suggested a single binding site, with K d of 122 ± 26.1 nM and a corresponding B max of 180 ± 6 f mol in 3.0 × 10 5 cells. The relative binding affinities of a series of modified PAR2 agonist peptides obtained from competition studies paralleled their relative EC 50 values for Ca 2+ mobilisation assays, indicating improved binding affinities by substitution with 2-furoyl at the N-terminus serine. Pretreatment of cells with trypsin reduced specific binding of [ 3H]2-furoyl-LIGRL-NH 2, demonstrating direct competition between the synthetic agonist peptide and the proteolytically revealed tethered ligand for the binding site of the receptor. In HCT-15 cells endogenously expressing PAR2, the binding of [ 3H]2-furoyl-LIGRL- NH 2 was displaced by addition of unlabeled ligands, Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) or 2-furoyl-LIGRL-NH 2. The relative binding affinity of 2-furoyl-LIGRL-NH 2 to SLIGKV-OH was comparable to its relative EC 50 value for Ca 2+ mobilisation assays. The binding assay was successfully performed in monolayers of PAR2 expressing NCTC2544 and human umbilical vein endothelial cells (HUVEC), in 96- and 24-well plate formats, respectively. These studies indicate that [ 3H]2-furoyl-LIGRL-NH 2 binds to human PAR2 at its ligand-binding site. The use of this radioligand will be valuable for characterising chemicals that interact to PAR2.

Original languageEnglish
Pages (from-to)255-263
Number of pages9
JournalBritish Journal of Pharmacology
Issue number2
Publication statusPublished - 1 May 2005


  • [ H]2-furoyl-LIGRL- NH
  • agonist
  • HCT-15 cells
  • NCTC7244 cells
  • protease-activated receptor-2 (PAR2)
  • radioligand-binding
  • trypsin


Dive into the research topics of 'Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [ <sub>3</sub>H]2-furoyl-LIGRL-NH <sub>2</sub>, to human PAR2'. Together they form a unique fingerprint.

Cite this